FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, b.c. 20045

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Schwab Gisela | | | | | | 2. Issuer Name and Ticker or Trading Symbol EXELIXIS, INC. [EXEL] | | | | | | | | eck all applic Directo | , | | son(s) to Issuer 10% Owner Other (specify | | |
|--|---|--|---|--------|--|---|--------|------------------------|-------------------------------------|--|------------------------|---|--|---|--|-------------------------------------|--|--|--|
| (Last) (First) (Middle) C/O EXELIXIS, INC. 1851 HARBOR BAY PARKWAY | | | | | 02 | 3. Date of Earliest Transaction (Month/Day/Year) 02/07/2020 | | | | | | | | Pres, Prod Dev & Med Aff & CMO | | | | | |
| (Street) ALAMEDA CA 94502 (City) (State) (Zip) | | | | _ 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Line | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| | | Tal | ole I - No | n-Deri | ivativ | re Se | curi | ties Ac | quirec | l, Dis | sposed o | f, or Bei | neficiall | y Owned | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | | ar) E | A. Deemed execution Date, fany Month/Day/Year) | | 3. Transa Code (| | 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 | | | Benefici Owned F | es ally Following | Form | : Direct I Indirect E str. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Reported Transact (Instr. 3 | tion(s) | | | (Instr. 4) | |
| Common Stock 02/07/2 | | | | | 7/2020 | 2020 | | | М | | 50,000 | A | \$5.51 | 375, | 375,122 ⁽¹⁾ | | D | | |
| Common Stock 02/07/2 | | | | | 7/2020 | 2020 | | S ⁽²⁾ | | 50,000 | D | \$18.37 | 325 | 5,122 | | D | | | |
| Common Stock | | | | | | | | | | | | | 14,8 | 380(4) | | | By 401(k) | | |
| | | | Table II | | | | | | | | oosed of, convertik | | | Owned | | • | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemo Execution if any (Month/Da | Date, | 4. Transaction Code (Instr. 8) | | ı of i | | 6. Date E Expiration (Month/I | n Dat | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4) | e s ally | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | | Date Exercisa | ıble | Expiration Date | Title | Amount or Number of Shares | | | | | | | |
| Option (right to | \$5.51 | 02/07/2020 | | | M | | | 50,000 | 09/18/20 | 14 ⁽⁵⁾ | 09/17/2020 | Common Stock | 50,000 | \$0 | 40,00 | 0 | D | | |

Explanation of Responses:

- 1. Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- 2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019.
- 3. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$18.14 to \$18.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- 4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 6, 2020.
- 5. The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017.

Remarks:

/s/ Jennifer Drimmer Rokovich, Attorney in Fact

02/07/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.